NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...

If you suffered losses exceeding $75,000 in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at ...

April 1 (Reuters) - The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in ...

GSK has developed a new propellant technology for inhaler devices that drastically reduces their use of greenhouse gases, which perhaps surprisingly account for nearly half (49%) of the group’s ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

A new antibiotic has been approved to treat urinary tract infections by the Food and Drug Administration for the first time in decades. It’s an oral pill called Blujepa from the London-based biopharma ...

Create a list of the investments you want to track.

The biggest stories of the day delivered to your inbox.